Cefditoren Pivoxil: Clinical, Pharmacological, and Microbiological Aspects

Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(2):111-129

Type
Journal article

Abstract

Cefditoren is a 3rd generation, broad-spectrum oral cephalosporin recently approved for the treatment of acute sinusitis, streptococcal pharyngitis/tonsillitis, bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and uncomplicated skin/skin structure infections in adult patients and children older than 12 years. This article reviews the antimicrobial activity, pharmacokinetics, evidence based data on the efficacy and safety of cefditoren by the MEDLINE search (up to the June 2013). In the article we also present the data on in vitro activity of cefditoren against recently collected in different regions of Russia community-acquired respiratory pathogens. Cefditoren has a broad spectrum of activity against major community-acquired aerobic bacterial pathogens, including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, and enterobacteria. This antimicrobial provides the best coverage for community-acquired respiratory pathogens and for bacteria causing community-acquired skin and soft tissue infections among all oral cephalosporins. Cefditoren is proven to be effective in the management of upper (sinusitis and pharyngitis/tonsillitis) and lower (community-acquired pneumonia and exacerbation of chronic bronchitis) respiratory tract infections, as well as uncomplicated skin/skin structure infections. According to the data reviewed we can conclude that based on its reported antimicrobial activity and data on its clinical efficacy and safety cefditoren has an excellent potential for empiric management of most commonly encountered bacterial community-acquired respiratory tract infections, and, with lesser extent, uncomplicated skin and soft tissue infections.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0